The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties by Jumbe, Samantha et al.
www.transonc.com
Trans la t iona l Onco logy Volume 12 Number 1 January 2019 pp. 134–142 134The Evolutionarily Conserved
Cassette Exon 7b Drives ERG's
Oncogenic PropertiesSamantha L. Jumbe*,1, Sean R. Porazinski*, 1,
SebastianOltean†, JasonP.Mansell*, BaharehVahabi*,
Ian D. Wilson* and Michael R. Ladomery*
*Faculty of Health and Applied Sciences, University of the
West of England, Coldharbour Lane, Frenchay, Bristol BS16
1QY, United Kingdom; †Institute of Biomedical & Clinical
Sciences, University of Exeter Medical School, St Luke's
Campus, Heavitree Rd, Exeter, EX1 2LU, United KingdomAbstract
The oncogene ERG encodes an ETS family transcription factor and is implicated in blood, vascular, and bone
development and in prostate, blood, and bone cancer. The ERG gene is alternatively spliced; of particular interest
is its cassette exon 7b which adds 24 amino acids, in frame, to the transcriptional activation domain. Higher exon
7b inclusion rates are associated with increased cell proliferation and advanced prostate cancer. The 24 amino
acids encoded by exon 7b show evolutionary conservation from humans to echinoderms, highlighting their
functional importance. Throughout evolution, these 24 amino acids are encoded by a distinct short exon. Splice-
switching oligonucleotides based on morpholino chemistry were designed to induce skipping of ERG exon 7b in
MG63 osteosarcoma and VCaP prostate cancer cells. Induction of exon 7b skipping reduced cell proliferation and
invasion, increased apoptosis in vitro, and reduced xenograft growth in vivo. We also show that ERG's exon 7b is
required for the induction of tissue nonspecific alkaline phosphatase. Together, these findings show that the
evolutionarily conserved cassette exon 7b is central to ERG's oncogenic properties.
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The ETS-related gene (ERG), discovered in 1987, also known as the v-ets
avian erythroblastosis virus E26 oncogene homolog, is a member of the
highly conserved ETS family of transcription factors [1]. ERG is of
fundamental importance in several developmental processes including
hematopoiesis, chondrocyte maturation, and bone development and in
apoptosis and cell migration [2]. TheERG gene is located on the q arm of
chromosome 21 and expresses at least 30 splice variants [3,4]. Of
particular interest are its cassette exons 7 and 7b; they are included inERG
transcripts at a higher rate in advanced prostate cancer [5,6]. Exon 7
encodes 27 amino acids and exon 7b encodes 24 amino acids, both in
frame. These extra amino acids are added to the transcriptional activation
domain (TAD) thought to influence the interaction of ERGwith protein
partners involved in transcriptional regulation [4]. Therefore, it is
reasonable to assume thatERG splice isoforms that include or exclude the
amino acids encoded by these cassette exons exhibit modified
transcriptional activities and distinct biological functions.
Tissue nonspecific alkaline phosphatase (TNSALP) is key to securing
an adequatelymineralized bonematrix. Loss-of-functionmutations in the
TNSALP gene result in hypophosphatasia (HPP), and variants of the
condition including perinatal HPP are lethal. A paucity of calcifiedcollagen is a striking feature of HPP, similar to rickets and osteomalacia
[7]. The clear similarities in the phenotypic presentation of HPP, rickets,
and osteomalacia suggest a role for vitamin D3 in the regulation of
TNSALP expression. The active metabolite of vitamin D3, calcitriol
(1,25D), promotes the development of mature bone-forming osteoblasts
in which TNSALP expression is increased. How 1,25D serves to control
TNSALP expression by osteoblasts is poorly understood, but it is
becoming clear that 1,25D requires signaling cooperation from selected
growth factors including TGFβ [8], EGF [9], and the pleiotropic lipid
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[10–12]. When the immature MG63 human osteoblast-like osteosarco-
ma cell line is co-stimulated with 1,25D and LPA, there is a demonstrable
synergistic effect resulting in increasedTNSALP expression. The fact that
LPA and 1,25D can together enhance osteoblast maturation explains the
effect of 1,25D on osteoblasts cultured in growth medium supplemented
with serum, a rich source of LPA bound to the albumin fraction [13]. The
potential role of ERG in TNSALP induction, and therefore in bone
mineralization, of relevance to osteosarcoma and other cancers, has not yet
been examined.
A critical role of ERG in bone and cartilage development and bone-
related pathologies including bone cancer is rapidly emerging. A study
carried out on chicken ERG reported that exon 7 is required for
chondrocyte development. Skipping of this exon is prevalent in
developing articular chondrocytes [14]. ERG lacking exon 7 maintains
cells in an immature state and prevents maturation into hypertrophic cells
and replacement of cartilage with bone, whereas expression of full-length
ERG with exon 7 included promotes chondrocyte maturation. The role
of the adjoining cassette exon 7b in chondrocyte development is not
known. The ERG gene is also implicated in osteoarthritis. A murine
model of osteoarthritis shows increased expression of ERG in articular
cartilage, and treatment with a 1,25D analogue eldecalcitol increased its
expression levels further [15]. Four weeks of histological assessment
indicated a reduction in the progression of osteoarthritis correlated with
increased ERG expression, suggesting that ERG contributes to resistance
to osteoarthritis in the early stages of disease. The relevance of cassette
exons 7 and 7b in the pathobiology of osteoarthritis is also not known.
In this study, splice-switching oligonucleotides (SSOs) were used to
induce exon 7b skipping in the MG63 osteoblast-like cell line and for
comparison also in the VCaP prostate cancer cell line. We show that
ERG's exon 7b is involved in regulating cell proliferation and apoptosis
and in invasion, consistent with its proposed oncogenic role [5,6]. Given
the importance of bone formation in the progression of osteosarcoma
(osteogenic sarcoma), we also set out to ascertain the potential involvement
of the cassette exon 7b of the ERG oncogene in osteoblast maturation.
TNSALP expression was induced in response to co-treatment with
1,25D and a phosphatase resistant analogue of LPA, (3S)1-fluoro-3-
hydroxy-4-(oleoyloxy)butyl-1-phosphonate (FHBP), which we have
previously shown enhances TNSALP expression [12,16]. We show that
skipping of ERG exon 7b inhibits TNSALP induction, ascribing a new
function to ERG and suggesting that ERG is also involved in bone
mineralization control in a splice isoform-specific manner.
Materials and Methods
All materials were obtained from Sigma-Aldrich unless otherwise stated.
Cell Lines
MG63 (ECACC, human osteoblast-like osteosarcoma cells,
catalogue no. 86051601) and VCaP cells (ECACC, human prostate
cancer vertebral metastasis, catalogue no. 06020201) were grown in
DMEM with 10% fetal bovine serum and 2 mM glutamine at 37°CTable 1. Primers Used for RT-PCR and RT-qPCR
Forward Primer (5′-3′)
ERG GAATATGGCCTTCCAGACGT
Primers for RT-qPCR are listed below
TNSALP CGTCGATTGCATCTCTGGGC
U13397 (spike) ACTCCGCTCAAGTGTTGAAGin 5% CO2 in a humidified incubator. Where serum starvation was
required, cells were cultured in phenol red-free DMEM:F12
supplemented with 100× stock of essential amino acids (5 mL per
500 ml medium) and glutamine (final concentration 2 mM).
Vivo-Morpholinos
All vivo-morpholino SSOs were purchased from Gene Tools, LLC,
USA. An SSOwas designed against both the 5′ and 3′ splice sites ofERG
exon 7b. The antisense sequence of the ERG exon 7b 5′ splice site SSO
(E7b5) was 5′-TCCGGTCCATGCTTTTGTGGGGACA-3′, and for
the ERG exon 7b 3′ splice site (E7b3), it was 5′-AAGGAAAACA
GACGTCCCCCACGUC-3′. The sequence for the control SSO,
targeting an intron in the β-globin gene variant associated with β-
thalassemia, was 5′-CCTCTTACCTCATTACAATTTATA-3′. Stocks
of each vivo-morpholino were prepared in sterile PBS at a concentration
of 0.5 mM. Each SSO has an octaguanidine dendrimer moiety to
facilitate delivery for cellular uptake and was added directly to media. For
experiments with VCaPs, the transfection reagent endoporter (Gene
Tools, LLC, USA) was used at 10 μM to facilitate uptake of SSOs.
RNA Extraction and cDNA Synthesis
Total RNA was extracted using the total RNA isolation mini kit
(Agilent Technologies Ltd.). All samples were treated with DNAse on
the columns using RNase-free DNase I provided in the kit. cDNA
was synthesized from 0.2-1 μg of total RNA using 200 U MuLV
reverse transcriptase (New England Biolabs), 40 U RNase inhibitor
(human placenta) (New England Biolabs), 0.5 mM dNTP, 25 μM
oligo-dT primers, and 10× reverse transcriptase buffer (500 mM
Tris–HCl pH 8.3, 750 mM KCl, 30 mM MgCl2, 100 mM DTT)
(New England Biolabs) in a final reaction volume 20 μl with added
nuclease-free water as required (Qiagen).
Semiquantitative Standard PCR and Gel Electrophoresis
Hot Start Taq 2× master mix (New England Biolabs) was used for
standard PCR. Reactions were set up at room temperature in a final
volume of 25 μl. The expression of ERGwas measured using the primers
listed in Table 1. The final concentration for each primer in the reaction
was 0.4 μM. PCRs were run as follows: initial denaturation at 95°C for
30 seconds, then 30 cycles of 95°C for 30 seconds, 54°C for 1 minute,
68°C for 1 minute, and a final extension at 68°C for 5 minutes.
Gel electrophoresis was carried out using 1.5% agarose gels stained
with 5 μl Midori Green Advance DNA stain (Geneflow) for every
100 ml of TAE. PCR products were loaded using purple 6× gel
loading dye (New England Biolabs) and run at 150 V for the first
10 minutes then at 100 V until adequate migration was achieved.
Gels were imaged on the Licor Odyssey Fc imaging system (Licor
Limited). Splice isoform ratios were determined by measuring the
relative brightness of PCR bands compared to each other using gel
Image Studio Lite software (Licor Limited). Percent spliced in (PSI, ψ)
was determined as a ratio of the intensity of the top band (exon
included) to the total signal of both bands.Reverse Primer (5′-3′)
CAAC GGTGGCCGTGACCGGTCCAGGCTG
GTCTCTTGCGCTTGGTCTCG
GGTGGCTTGTAGGCAATGAA
Figure 1. Evolutionary conservation of ERG's cassette exon 7b. (A)
Alignment of the 24 amino acids encoded in frame by exon 7b in a
range of species: Homo sapiens (human) NP_001129626.1, Mus
musculus (mouse) NP_598420.1, Gallus gallus (chicken)
XP_015155736.1, Danio rerio (zebrafish) NP_001008616.1, and
Strongylocentrotus purpuratus (sea urchin) XP_011672837.1. A
putative ERK phosphorylation site is shown. (B) Alignment of a
sample of corresponding genomic sequences surrounding the
splice sites of the cassette exon. Sequences were obtained using
BLAST (NCBI) and aligned with Clustal Omega.
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Whole cell protein lysates were prepared from washed cell pellets
using RIPA buffer [10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1%
Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 140 mM
NaCl] supplemented with protease inhibitor tablets (ThermoFisher).
After a 30-minute incubation with periodical vortexing, lysates were
centrifuged for 15 minutes at 12,000×g at 4°C for clarification.
Samples were transferred to fresh tubes and quantified using the BCA
kit (Thermofisher) using a BSA standard curve.
Immunoblotting was carried out using 10 to 20 μg of total cell lysate.
Samples were added to 2× Laemlli sample buffer and heated for
5 minutes at 100°C. Proteins were separated by handcast SDS-
polyacrylamide gel electrophoresis gels on the Mini-PROTEAN Tetra
vertical electrophoresis gel apparatus (Bio-Rad) and subsequently wet-
transferred at 50 V for 2 hours on the Trans-Blot Turbo transfer
apparatus (Bio-Rad). PVDF membranes were blocked with 5% (w/v)
skimmedmilk in Tris-buffered saline with 0.1%Tween-20 (TBST) for 1
hour at room temperature and probed with 1:1000 ERG (Abcam,mouse
monoclonal, ab92513) and 1:10,000 β-actin primary antibodies (Abcam,
polyclonal, ab8229) diluted inTBST overnight at 4°C. After three washes
in TBST, membranes were incubated in 1:2000 HRP-linked anti-rabbit
or anti-mouse IgG secondary antibody (New England Biolabs) for 2
hours at room temperature. Following a final three TBST washes,
membranes were incubated in Luminata Forte Western HRP substrate
(Millipore) for chemiluminescent detection for 2 minutes prior to image
acquisition using the Licor Odyssey Fc imaging system.
Real-Time Quantitative PCR (RT-qPCR)
RT-qPCRwas performed in compliance withMIQE guidelines [17]. A
SensiFAST SYBR Hi-ROX kit (BIOLINE UK, London) was used for
qPCR. An exogenous spike made from the U13397 cDNA clone for the
small RuBisCO subunit ofArabidopsis thalianawas produced using in vitro
transcription (The Arabidopsis Information Resource, TAIR). Each RNA
sample was spiked with 5 ng of the RuBiSco RNA spike prior to cDNA
synthesis. During qPCR, the spike signal was measured in parallel to the
genes of interest. Normalization was then carried out using the mass of the
spike calculated from standard curve to calculate a multiplication factor for
each sample relative to the sample with the highest spike expression. The
mass of RNA for each gene of interest was then normalized using this
multiplication factor. The primers were used at a final concentration of
200 nmol per reaction. The primer sequences are listed in Table 1. Serial
dilutions of known amounts of the U13397 plasmid DNA were used to
produce standard curves in order to facilitate quantitation. qPCR analysis
was performed on a StepOne Plus real-time thermocycler (Life
Technologies). Following a 2-minute activation step at 95°C, 45 cycles
of 5 seconds at 95°C and 30 seconds at 57°C were carried out.
Analysis of Cell Proliferation
After treatments, media were removed and cells were washed three
times in PBS. The cells were then fixed in 3.7% (w/v) paraformaldehyde
for 15 minutes at room temperature. The paraformaldehyde was
discarded, and after three PBS washes, a solution of 0.1% (v/v) Triton
X-100 was applied for 5 minutes to permeabilize the cells. Cells were
then blocked in 3% FBS (in PBS) for 30 minutes before being
incubated with Ki67 primary antibody (Abcam) in blocking solution
(1:200) for 2 hours at room temperature. Three PBS washes were
followed by incubation for 1 hour in fluorophore-conjugated secondary
antibody (Thermofisher Scientific, 1:2000) at room temperature, three
more PBS washes, and a 2-minute incubation in 2 μg/ml Hoechst3342. Images of each well were taken in six fields of view using the
Eclipse 80i microscope (Nikon) using filters to detect the Ki-67 foci and
Hoechst counterstain. ImageJ software was used to calculate the
percentage of Ki67-positive cells.
Apoptosis Assay
After seeding in 6-well plates, MG63 cells were treated with SSOs for
48 and 72 hours. Forty-five minutes prior to the end of the incubation
period, the caspase 3/7 reagent (CellEvent) made up in prewarmed PBS
was added. Images of six representative fields of viewwere taken for each
sample using the 20× objective on the Eclipse 80i microscope (Nikon).
Transwell Invasion Assay
For the invasion assay, PET inserts (membrane pore size, 8 μm;
Millipore) were coated with 50 μl of Geltrex Matrix (ThermoFisher)
diluted 1:1 in serum-free medium for at least 2 hours and up to 24 hours
to create an artificial basement membrane. Inserts were set up in 24-well
plates. MG63 cells were treated with SSOs for 24 hours and then
harvested. Subsequently, 1 × 105 cells in 100 μl serum-free medium
were added to the upper chamber of the insert. A total of 600 μl of
medium supplemented with 10% FBS was added to the lower chamber
of the 24-well plate. Following 24 hours at 37 °C, the cells remaining on
the upper membrane of the insert were removed and inserts washed in
PBS. After 15-minute fixation in methanol and 2-minute staining with
hematoxylin, the inserts were air dried prior to imaging of six
representative fields of view using a camera attached to a light microscope
(20× objective). The number of cells adhering to the lower membrane of
the inserts was counted.
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Two-month-old male nude mice (CD1; Charles River, USA) were
housed under pathogen-free conditions. All animal operations were
approved by the Animal Ethics Committee, University of Exeter, U.K.
A minimum of six mice were used per experimental group.
For heterotopic xenografts, 7 × 106MG63 cells resuspended in 100 μl
of PBS were injected subcutaneously into the right flank of mice. Tumors
were measured with a caliper twice weekly, and tumor volume was
calculated according to the formula: [(length + width)/2]*length*width.
Once tumors reached 3mmby 3mm in size, 12.5 mg/kg of SSO or PBS
was administered by intraperitoneal injection twice weekly.
Measurement of TNSALP Activity
TNSALP activity can be measured by the generation of p-
nitrophenol (p-NP) from p-nitrophenylphosphate (p-NPP) under
alkaline conditions. Cells were seeded into 96-well plates in serum
containing medium and given time to adhere to the cell culture vessel
prior to being starved in serum-free phenol red–free DMEM/F12
medium overnight.Wells were dosed with 3 μMof SSOs in the serum-
free medium and incubated for 24 hours. Subsequently, FHBP and
1,25D were added to the relevant wells as well as an additional dose of
SSO to maintain the expression of ERG exon 7b skipped isoforms.
Following another 24-hour incubation, the treatment medium was
removed and replaced with 100 μl resazurin reagent made up in serum-Figure 2. SSO-inducedERG exon7b skipping inMG63andVCaPcells. (A
SSOs. The positions and sequences of the SSOs and the positions of E
SSO resulted in near-complete exon 7b skipping in MG63 and VCaP ce
shown. (C) Ninety-six hours after transfection with E7b5 and E7b3 SSO
increased in both cell lines. A β-actin loading control was included in tfree medium (10 μg/ml) 2-4 hours prior to the end of the incubation
period in order to assess cell viability. The same volume was added to
control wells containing no cells as a negative control. The plates were
then read at 570 nm and 620 nm in a plate reader (FLUOstar
OPTIMA, BMG Labtech) to obtain readings for cell viability.
The resazurin reagent was removed, and the monolayers were washed
for 5minutes in fresh serum-freemedium to remove the residual resazurin
and its metabolites. Following this, the medium was removed and the
monolayers lysed with 50 μl of TNSALP lysis buffer [25 mM sodium
carbonate (pH 10.3) and 0.1% (v/v) Triton X-100]. After 2 minutes,
each well was treated with 100 μl of 15 mM p-NPP (di-Tris salt, Sigma-
Aldrich) in 250 mM sodium carbonate (pH 10.3), 1 mM MgCl2. The
cell culture plates were then returned to the cell culture incubator for
1 hour and transferred to the plate reader. An ascending series of p-NP
concentrations (10-500 μM) prepared in the incubation buffer were
added to empty wells on the plate to enable quantification of product and
the absorbance read at 405 nm. Reported total ALP activity was corrected
to cell viability determined with the resazurin assay.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation was performed using the Imprint
Chromatin Immunoprecipitation Kit (Sigma, UK) according to the
manufacturer's protocol. Briefly, 1 × 106 MG63 cells were incubated
for 10 minutes with 1% formaldehyde at room temperature to allow) The 5′ and 3′ splice sites of exon7bwere targetedusingmorpholino
RG PCR primers are indicated. (B) Treatment with 3 μM of the E7b3
lls 24 hours after transfection. The percent spliced in (PSI, ψ) ratio is
s, levels of ERG protein isoforms lacking the 24 amino acids (52 kDa)
he western blot (cropped to highlight relevant bands).
Figure 3. Effect of SSO-induced exon 7b skipping on cell proliferation (A,B) and apoptosis (C,D) in MG63 and VCaP cells. After 72 hours of
treatment with 3 μM SSO, Ki-67 expression was determined using immunofluorescent microscopy. Ki-67 foci were overlaid with DAPI.
The graphs show the percentage of Ki-67–positive cells **P = ≤ .01, N = 3 repeats. Caspase 3/7–positive foci were quantified using
immunofluorescent microscopy to determine apoptosis in MG63 (C) and VCaP (D) cells following treatment with 3 μM SSO for 72 hours.
The percentage of caspase 3/7–positive cells is shown (*P b 0.05, **P b 0.01, ***P b 0.001). Error bars show 95% confidence interval
(95% CI); N = 3 repeats.
Figure 4. Effect of SSO-induced exon 7b skipping on invasion and xenograft growth. Transwell invasion assay in MG63 cells (A) and VCaP
cells (B) 48 hours following SSO transfection. Fold change is relative to PBS control; N = 3 repeats in each case. (C) A total of 7 × 106
MG63 cells were injected subcutaneously into 2-month-old immunocompromised nude mice which were dosed intraperitoneally with
saline, control SSO, or E7b3 SSO at 12.5 mg/kg twice weekly once tumors reached 3 mm by 3 mm in size. Tumors were measured with a
caliper twice weekly over a period of 56 days. (*P b 0.05, ***P b 0.001). Error bars in (A) and (B) show 95% confidence interval (95% CI);
N = 3 repeats. For the xenograft experiments (C) groups of six mice were used.
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sheared to produce fragments of ~1000 bp using a sonicator, six
pulses for 15 seconds at 50% power output followed by incubation
on ice for 60 seconds after each pulse. The DNA-protein mixture was
incubated in a well of a cell culture plate coated with 3 μg of anti-
ERG antibody (Santa Cruz, UK), 1 μg RNA polymerase II antibody,
or 3 μg nonspecific IgG at room temperature for 3 hours. This was
followed by six washes with the IP wash buffer. The cross-linked
DNA-ERG complexes were released using Proteinase K at 65°C for
15 minutes. The DNA was cleaned up and eluted using GeneElute
Binding Colum (Sigma, UK). PCR was then carried out using the
following primers: ALPLF 5′-TCGCTGGAGGCATTCAAAC-3′
and ALPLR 5′-CCCCTCTTTAACAGGCAGAC-3′.
Statistical Analysis
The Kruskal-Wallis test and, where applicable, the Dunn's test were
carried out. Significance levels are indicated by asterisks where * = P b .05,Figure 5. TNSALP induction is attenuated by SSO-induced skipping of e
measured indirectly via the production of p-NP. (B) Cell viabilitymeasurem
viability. (C) TNSALP expression levels weremeasured by qPCR, expresse
not induce exon 7b skipping.N = 5 repeats in each case. (E) Analysis of t
binding site 960 bp upstream of the transcriptional start site. Primer po
analysis; TNSALP promoter DNA is present in the ERG immunoprecipita** = P b .01, and *** = P b .001. Data are reported as means, and error
bars show 95% confidence intervals.Results
Evolutionary Conservation of ERG's Cassette Exon 7b
We examined the evolutionary conservation of ERG's cassette exon
7b (Figure 1). We observed putative ERG orthologues across the
evolutionary tree. We noted a 524–amino acid transcription factor in
the sea urchin Strongylocentrotus purpuratus that aligns throughout the
protein with human ERG (53% identity), with strongest conservation
in the C-terminal ETSDNA-binding domain.We also observed strong
conservation with sea urchin ERG in several pockets of the N-terminal
regulatory domain, including the 24 amino acids encoded by exon 7b.
Next, we aligned the exon 7b 24 amino acids in ERG in several species
including sea urchin and several vertebrates and noticed amino acid
sequence conservation, especially in the first 10 amino acids. Thesexon 7b. (A) Treatment with 1,25D and FHBP induced TNSALP activity
ents confirm that changeswere not caused by reduced cell number or
d as% of total RNA input. (D) The addition of 1,25D or FHBP alone did
he TNSALP promoter reveals the presence of at least one putative ERG
sitions and sequence are shown. (F) Chromatin immunoprecipitation
te. IgG, negative control; RNA polymerase II, positive IP control.
Figure 5. (continued).
140 Exon 7b Drives ERG's Oncogenic Properties Jumbe et al. Translational Oncology Vol. 12, No. 1, 2019include two aromatic residues, followed by a proline, and then a conserved
threonine or serine. These amino acids are consistent with a potential
ERK docking site, FxFP, known as ‘DEF’ (docking site for ERK FXF)
[18]. At the end of the 24–amino acid sequence, there are also 2 conserved
basic residues (Figure 1A).
We then examined whether or not these amino acids are encoded
by a distinct exon throughout evolution. Analysis of genomic
sequences in four species indicates that the 24 amino acids are, in all
cases, encoded by a distinct 72-base exon. We suggest that the use of a
small cassette exon to regulate the inclusion of these 24 amino acids is
an ancient and common feature of the ERG gene (Figure 1B).
SSOs Induce ERG Exon 7b Skipping
SSOs were designed to target, through sterical hindrance, the splice
acceptor (E7b3) and donor (E7b5) sites of exon 7b in ERG (Figure 2A).
MG63 osteosarcoma cells were treated with 0.5, 1, and 3 μM of each
SSO for 24 hours, after which the rates of ERG exon 7b inclusion were
measured (Figure 2B). A control SSOwas included in addition to a PBS
vehicle control. The most efficient exon skipping was observed with the
E7b3 SSO at 3 μM with almost undetectable exon 7b [0.01 PSI (ψ),
where ψ is the proportion of exon inclusion], compared to 0.22 ψ
obtained with the E7b5 SSO. There was detectable exon skipping at the
lower 1-μM dose with the E7b3 SSO. The control SSO did not cause
any significant changes to ERG exon 7b skipping. Next, we tested the
most efficient SSO, E7b3, in VCaP prostate cancer cells and observed a
similar, convincing shift in PSI value from 0.81 to 0.32 using 3 μM
E7b3. Exon 7b skipping was confirmed at the protein level (Figure 2C).ERG Exon 7b Skipping Reduces Cell Proliferation and
Invasion, Increases Apoptosis, and Reduces Xenograft Growth
Having established that exon 7b skipping could be achieved with
SSOs, we proceeded with the best performing SSO E7b3 and
examined the biological roles of exon 7b in MG63 and VCaP cells
using a range of cell biology assays. SSO-induced exon 7b skipping
resulted in a significant decrease in cell proliferation in both cell lines
measured via Ki-67 staining (Figure 3, A and B). In parallel, we
observed a significant increase in apoptosis as a result of exon 7b
skipping, measured through caspase 3/7 staining (Figure 3, C and D).
SSO-induced exon 7b skipping also resulted in reduced cell
invasion assayed through a Transwell assay (Figure 4, A and B). We
also performed a mouse xenograft experiment (Figure 4C). A total of
7 × 106 MG63 cells were injected subcutaneously into 2-month old
nude mice. Tumor volumes were measured over a period of 56 days.
Whereas we did notice a partial effect with the control SSO, the E7b3
SSO achieved the greatest reduction in tumor growth. Taken
together, these results are consistent with exon 7b inclusion driving
the oncogenic properties of ERG.
TNSALP Induction Is Attenuated by Exon 7b Skipping
Next, we considered the effect of exon 7b skipping on the ability of
osteoblast-like MG63 cells to differentiate, measured through the
expression of TNSALP. Serum-starved MG63 cells were first treated
with SSOs for 24 hours. After 24 hours, the cells were treated with
1,25D and FHBP and given an additional dose of SSO. After a
further 24 hours, alkaline phosphatase activity was assessed using the
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(p-NPP) conversion to p-nitrophenol (p-NP), producing a yellow color
quantified by measuring absorbance at 405 nm. As expected, the co-
stimulation of MG63 cells with 1,25D and FHBP resulted in an
increase in p-NP production consistent with TNSALP induction. In
the presence of E7b3 SSO, the increase of p-NP was significantly lower
compared to the 1,25D and FHBP co-treatments alone. Control SSO
with 1,25D and FHBP did not cause a significant attenuation of p-NP
levels (Figure 5A). A resaruzin cell viability assay confirmed that changes
observedwith the TNSALP activity assay were not due to changes in cell
number or viability (Figure 5B).
RT-qPCR was used to measure the expression of the TNSALP gene.
We observed significantly increased expression in the 1,25D and FHBP
co-treated cells and in the presence of the control SSO. The reduction of
TNSALP expression in the presence of E7b3 SSO was statistically
significant (Figure 5C), in agreement with the TNSALP assay results. To
confirm thatERG exon 7b skipping was occurring both prior to and after
1,25D and FHBP treatment, a standard PCR analysis of ERG exon 7b
skipping was carried out. Exon 7b skipping was detected in E7b3 SSO-
treated cells (Figure 5D). Treatment with 1,25D and FHBP, either alone
or in combination, did not alter ERG exon 7b skipping rates.
We examined the TNSALP promoter for the presence of putative
ERG binding sites (conforming to the core GGAA sequence, Figure 5E).
We noted the presence of at least one putative ERG binding site,
AGAGGAAACG, 930 bp upstream of the transcription start site. We
designed primers flanking this site, covering 264 bp of promoter
sequence, and performed a chromatin immunoprecipitation assay
(Figure 5F). ERG co-immunoprecipitated with this sequence but not
with the GAPDH promoter (data not shown), suggesting that ERG
binds to the TNSALP promoter, directly regulating its transcription.
Discussion
Alternative splicing of ERG cassette exon 7b has previously been shown
to alter ERG's biological functions. Cell proliferation increases when
exon 7b is included [5], and we have previously reported that higher
exon 7b inclusion rates are associated with advanced prostate cancer [6].
We observe that the 24 amino acids encoded in frame by exon 7b in
humans are conserved throughout evolution and are encoded by a
distinct, short 72-base exon. In humans, inclusion of this cassette exon is
likely regulated by trans-acting splice factors whose identity remains to
be determined. ERG's contribution to the regulation of cell
proliferation, apoptosis, and differentiation is, we suggest, regulated
by alternative splicing. The physiological importance of exon 7b is
further underlined by the presence of an evolutionarily conserved
putative ERK (extracellular signal regulated, mitogen-activated protein
kinase) docking site (FxFP) within the 24 amino acids encoded by exon
7b [19]. The phosphorylation of ERG is required to promote the
migration of prostate cancer cells and the transcription of migration-
associated genes [20]. ERG phosphorylation is stimulated via VEGF
through the MAPK/ERK cell signaling pathway, promoting sprouting
angiogenesis, a hallmark of cancer [21].
We designed SSOs based on morpholino chemistry that targeted
both splice sites of exon 7b. The SSO that targets the 3′ splice site was
the most efficient. Having established an appropriate dose, we observed
that, 48 hours after transfection, the 3′ splice site SSO (E7b3) achieved
near complete skipping of exon 7b. SSO-induced exon 7b skipping
significantly reduced cell proliferation, increased apoptosis, and reduced
cell invasion. We also performed a xenograft experiment using MG63
cells. We observed that the E7b3’ SSO significantly reduced the growthof the xenografted cells. SSOs that prevent the inclusion of exon 7b
could therefore have therapeutic potential.
We also wanted to examine if cassette exon 7b contributes to the
maturation of osteoblast-like MG63 osteosarcoma cells, measured via the
activation of TNSALP. Addition of 1,25D and FHBP to the MG63 was
used to establish amaturationmodel inwhich increasedTNSALP activity
was observed [12,16]. There was a significant attenuation of TNSALP
induction in the presence of E7b3 SSO, confirmed by reduced mRNA
levels and at a protein level via decreased p-NP production. A study by
Iwamoto and colleagues had previously identified a reduction in alkaline
phosphatase activity and mineralization when the C-1-1 ERG isoform
lacking the 81-bp cassette exon 7was expressed [14].Our findings suggest
that exon 7b is also required for the induction of alkaline phosphatase
activity. Exons 7 and 7b both encode for part of theTADdomain of ERG
that, we presume, modulates the transactivation activities of the ERG
transcription factor during development. In both mouse and chicken
models,ERG is involved in chondrocyte development in a splice isoform-
specific manner [14,22,23]. However, the extent to which both exon 7
and 7b skipping is required, the effect of each cassette exon on ERG's
transcriptional activity, and whether or not the regulation of their
alternative splicing is coordinated are not yet known.
Previous characterization of the TNSALP promoter revealed the
presence of binding sites for the transcription factor SP1 [24–26].
The inhibition of SP1 promoter binding by mithramycin A in the
presence of 1,25D/FHBP co-treatment reduced the levels of
TNSALP [27], suggesting that the SP1 promoter binding sites may
have biological relevance. It is conceivable that ERG also activates
TNSALP transcription directly, in an isoform-specific manner
(ERG + exon 7b), and this is consistent with our chromatin
immunoprecipitation result. Alternatively, ERG's involvement in
TNSALP activation could also be indirect; there is evidence that ERG
is involved in the activation of SP1 itself, and ERG physically interacts
with SP1 [28]. The precise mechanisms remain to be determined, but
we propose that ERG and SP1 transcription factors work together to
regulate TNSALP expression and that ERG plays a role in the
regulation of bone mineralization via interaction with 1,25D and
LPA-sensitive pathways. The ability of ERG to activate TNSALP and
therefore to promote bone matrix mineralization is of significance to
the development and progression of osteosarcoma [29,30] and
potentially of other cancers in which ERG is implicated.
In conclusion, this study affirms the evolutionary conservation of
ERG's cassette exon 7b and of the 24 amino acids it encodes. We
confirm the importance of exon 7b in regulating cell proliferation,
apoptosis, migration, and invasion. We also present a novel role for the
ERG transcription factor and its cassette exon 7b in the induction of
TNSALP. We have successfully designed SSOs that target ERG exon
7b, causing efficient skipping of the exon. SSOs that cause skipping of
ERG's cassette exon 7b could provide a novel therapeutic avenue.
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